Trademark Overview
On Wednesday, September 18, 2024, a trademark application was filed for AGOMAB with the United States Patent and Trademark Office. The USPTO has given the AGOMAB trademark a serial number of 79408296. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, October 31, 2024. This trademark is owned by AgomAb Therapeutics NV. The AGOMAB trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical and medical preparations; chemical preparations for medical and pharmaceutical purposes; pharmaceutical and medical preparations for use in relation to fibrosis, fibrotic diseases, fibrostenosing Crohn's disease, idiopathic pulmonary fibrosis, skin diseases, eye diseases, organ failure, liver disease, kidney disease, inflammatory disease, degenerative disease, autoimmune disease, and the treatment of diseases requiring tissue repair; small molecule drugs; antibodies; pharmaceutical and medical preparations incorporating antibodies.
Scientific research and development services; clinical trials; research and development in the fields of fibrosis, fibrotic diseases, fibrostenosing crohn's disease, idiopathic pulmonary fibrosis, skin diseases, eye diseases, organ failure, liver disease, kidney disease, inflammatory disease, degenerative disease, autoimmune disease, and the treatment of diseases requiring tissue repair; research and development in the fields of small molecules and antibodies; research, development and design of pharmaceutical and medical preparations; drug development and discovery services; laboratory and medical laboratory research and development services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy, advisory and information services relating to all the aforesaid.
